U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H32N2O5
Molecular Weight 416.5106
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RAMIPRIL

SMILES

[H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC

InChI

InChIKey=HDACQVRGBOVJII-JBDAPHQKSA-N
InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16398929

Ramipril (sold under the brand name Altace ) is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitors. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril is indicated for the treatment of hypertension, to lower blood pressure; also used to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes; in addition, this drug is used to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.

CNS Activity

Originator

Approval Year

1991
113
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
ALTACE

Approved Use

Reduction in Risk of Myocardial Infarction, Stroke, and Death from Cardiovascular Causes Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). Hypertension Ramipril capsules are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using ramipril capsules, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ramipril capsules do not have a similar risk. (See WARNINGS.) In considering use of ramipril capsules, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See WARNINGS, Angioedema.)

Launch Date

1991
Preventing
Approved
8429
ALTACE

Approved Use

Reduction in Risk of Myocardial Infarction, Stroke, and Death from Cardiovascular Causes Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). Hypertension Ramipril capsules are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using ramipril capsules, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ramipril capsules do not have a similar risk. (See WARNINGS.) In considering use of ramipril capsules, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See WARNINGS, Angioedema.)

Launch Date

1991
Primary
Approved
8429
ALTACE

Approved Use

Reduction in Risk of Myocardial Infarction, Stroke, and Death from Cardiovascular Causes Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). Hypertension Ramipril capsules are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using ramipril capsules, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ramipril capsules do not have a similar risk. (See WARNINGS.) In considering use of ramipril capsules, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See WARNINGS, Angioedema.)

Launch Date

1991
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
43.8 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2533075
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RAMIPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
24 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/6097458
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMIPRILAT unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
197 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/2533075
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RAMIPRIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
414 μg × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/6097458
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RAMIPRILAT unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Other AEs: Headache, Cough...
Other AEs:
Headache (13%)
Cough (33%)
Dizziness (13%)
Asthenia (19%)
Cramps (4%)
Diarrhea (4%)
Nausea (8%)
Palpitations (1%)
Dyspnea (1%)
Tinnitus (1%)
Malaise (3%)
Pruritus (1%)
Dry mouth (1%)
Polyuria (3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Other AEs: Dizziness, Vertigo...
Other AEs:
Dizziness (6%)
Vertigo (6%)
Asthenia (4%)
Nausea (3%)
Headache (2%)
Abdominal pain (1%)
Gastrointestinal disorder (1%)
Rash (1%)
Cough increased (1%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
AEs

AEs

AESignificanceDosePopulation
Dry mouth 1%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Dyspnea 1%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Palpitations 1%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Pruritus 1%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Tinnitus 1%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Dizziness 13%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Headache 13%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Asthenia 19%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Malaise 3%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Polyuria 3%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Cough 33%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Cramps 4%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Diarrhea 4%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Nausea 8%
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
unhealthy, 18-75
n = 661
Health Status: unhealthy
Condition: Hypertension
Age Group: 18-75
Sex: M+F
Population Size: 661
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725026/
Abdominal pain 1%
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Cough increased 1%
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Gastrointestinal disorder 1%
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Rash 1%
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Headache 2%
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Nausea 3%
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Asthenia 4%
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Dizziness 6%
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Vertigo 6%
20 mg 1 times / day multiple, oral (max)
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Co-administed with::
hydrochlorothiazide(25 mg; 1/day)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
unhealthy, 55.7 years (range: 21-88 years)
n = 555
Health Status: unhealthy
Condition: Essential hypertension
Age Group: 55.7 years (range: 21-88 years)
Sex: M+F
Population Size: 555
Sources:
https://pubmed.ncbi.nlm.nih.gov/1725024/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CES1
22

CES2
28
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
PEPT1
22
 yes
PEPT2
12
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CES2
28
 no
CES1
22
 yes
PubMed

PubMed

TitleDatePubMed
Mechanical vs intrinsic components in the improvement of brachial arterial compliance. Comparison of the effects of atenolol versus ramipril in hypertensive patients.
2001
[Activity of the renin-angiotensin-aldosterone system and its impact on the effectiveness of treatment of chronic heart failure in patients with pulmonary tuberculosis].
2001
Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance.
2001
Differential regulation of cathepsin B and prorenin gene expression in renal juxtaglomerular cells.
2001
An ACE inhibitor to coronary patients: ramipril reduces mortality according to HOPE trial.
2001 Apr
Use of 7-fluoro-4-nitrobenzo-2-oxo-1,3-diazole (NBD-F) for the determination of ramipril in tablets and spiked human plasma.
2001 Apr
Study at up to 700 sites will build on landmark HOPE trial.
2001 Apr-May
[Effect of a non-antihypertensive dose of ramipril on the plasma and tissue renin-angiotensin system in 27 TGR (mRen2) rats].
2001 Aug
HOPE for patients with Type 2 diabetes: an application of the findings of the MICRO-HOPE substudy in a British hospital diabetes clinic.
2001 Aug
The HOPE study: comparison with other trials of secondary prevention.
2001 Aug
Impaired angiotensin II regulation of renal C-type natriuretic peptide mRNA expression in experimental diabetes mellitus.
2001 Aug 15
Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: importance of kinins and influence on angiotensin II type 1 receptor signaling pathway.
2001 Aug 21
[Diabetic nephropathy. Smoking also damages the kidney].
2001 Aug 23
Changes in vasoconstrictive hormones, natriuretic peptides, and left ventricular remodeling soon after anterior myocardial infarction.
2001 Dec
Diabetes and the HOPE study: implications for macrovascular and microvascular disease.
2001 Jan
Future perspectives and implications.
2001 Jan
Pharmacoeconomic impact of HOPE.
2001 Jan
Modifying the natural history of atherosclerosis: the SECURE trial.
2001 Jan
Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade.
2001 Jul
Right atrial function in hypertensive patients: effects of antihypertensive therapy.
2001 Jul
Potentiation of kinin analogues by ramiprilat is exclusively related to their degradation.
2001 Jul
Bradykinin metabolism in the isolated perfused rabbit heart.
2001 Jul
Simultaneous determination of hydrochlorothiazide and several inhibitors of angiotensin-converting enzyme by capillary electrophoresis.
2001 Jul 27
Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study.
2001 Jul 31
Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy.
2001 Jul-Aug
Renal insufficiency predicts cardiovascular disease in high-risk individuals: the benefit of ramipril in the HOPE study. Heart Outcomes and Prevention Evaluation.
2001 Jul-Aug
The African American Study of Kidney Disease and Hypertension (AASK): new findings.
2001 Jul-Aug
[Decreased platelet aggregation during angiotensin-converting enzyme inhibitor therapy. Results of a pilot study].
2001 Jun 15
Differential effects of angiotensin AT1 and AT2 receptors on the expression, translation and function of the Na+-H+ exchanger and Na+-HCO3- symporter in the rat heart after myocardial infarction.
2001 Jun 15
[Therapeutic perspectives: association of ACE inhibitors and angiotensin receptor blockers].
2001 Mar-Apr
ACE inhibitor inhibits atherosclerosis.
2001 May
[Severe hypoglycemia secondary to angiotensin-converting-enzyme inhibitors in the absence of diabetes mellitus. Report of a case].
2001 May-Jun
Prevention, protection, and the intrarenal renin-angiotensin systems.
2001 Nov
The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study.
2001 Nov
Simvastatin reverses impaired regulation of renal oxygen consumption in congestive heart failure.
2001 Nov
Clinical trials report. The effect of Ramipril versus Amlodipine on renal outcomes in hypertension nephrosclerosis.
2001 Oct
Ramipril and the development of diabetes.
2001 Oct 17
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.
2001 Oct 2
[Atherosclerosis. High ACE activity in plaque: risk of rupture!].
2001 Oct 25
Inhibition of cyclooxygenase-2 attenuates urinary prostanoid excretion without affecting renal renin expression.
2001 Sep
What is the best treatment for slowing the progression to end-stage renal disease (ESRD) in African Americans with hypertensive nephropathy?
2001 Sep
What is the relevance of the HOPE study in general practice?
2001 Sep
Enantioseparation of the anticoagulant drug phenprocoumon in capillary electrophoresis with UV and laser-induced fluorescence detection and application of the method to urine samples.
2001 Sep
Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway.
2001 Sep
Inhibitors of bradykinin-inactivating enzymes decrease myocardial ischemia/reperfusion injury following 3 and 7 days of reperfusion.
2001 Sep
The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?
2001 Sep
Can ACE inhibitor therapy prevent end-stage renal failure?
2001 Sep 3
[Ramipril can do more. Halting progression of atherosclerosis].
2001 Sep 6
[Achieving vascular protection. ACE inhibitor lowers not only blood pressure].
2001 Sep 6
Blacks with hypertension, renal insufficiency, and baseline proteinuria benefit more from ACE inhibition than from calcium channel blockade.
2001 Sep-Oct
Patents

Patents

06407262
2
20010002262
19
JP1066130A
10
JP2001501189A
7
JP2001508027A
37
JP2002535367A
24
JP2002536332A
38
JP2002538172A
25
JP2002541106A
98
JP2002541233A
400
JP2003501461A
2
JP2003503381A
35
JP2003507418A
31
JP2003508349A
45
JP2003515526A
462
JP2004531567A
7
JP2005500299A
34
JP2005527208A
2
JP2005527462A
21
JP2007514770A
75
JP2007518794A
2
JP2007520453A
33
JP2007524644A
48
JP2007525670A
148
JP2008167697A
2
JP2011506455A
51
JP2011510003A
48
JP2011510067A
57
JP2011524416A
138
JP2011528275A
455
JP2012500806A
10
JP2013544275A
6
JP4139440B2
7
JP4606172B2
28
JP4687863B2
2
JP4705912B2
47
JP4729259B2
38
JP4733348B2
2
JP4746258B2
2
JP4800961B2
2
JPH00219326A
2
JPH01165596A
2
JPH02121922A
13
JPH0219326A
2
JPH04179441A
2
JPH04308533A
5
JPS6466130A
5

Sample Use Guides

In Vivo Use Guide
Hypertension: The recommended initial dose for patients not receiving a diuretic is 2.5 mg once a day. Adjust dose according to blood pressure response. The usual maintenance dosage range is 2.5 mg to 20 mg per day administered as a single dose or in two. Myocardial Infarction, Stroke, and Death from Cardiovascular Causes: Initiate dosing at 2.5 mg once daily for 1 week, 5 mg once daily for the next 3 weeks, and then increase as tolerated, to a maintenance dose of 10 mg once daily. equally divided doses. In some patients treated once daily, the antihypertensive effect may diminish toward the end of the dosing interval. Heart Failure Post-Myocardial Infarction: the recommended starting dose is 2.5 mg twice daily (5 mg per day). A patient who becomes hypotensive at this dose may be switched to 1.25 mg twice daily. After one week at the starting dose, increase dose (if tolerated) toward a target dose of 5 mg twice daily, with dosage increases being about 3 weeks apart.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: The effect of ramipril on DNA synthesis, cell proliferation and PDGF A and B chain gene expression in fetal calf serum (FCS)-activated cultured human glomerular mesangial cells was investigated. Ramipril significantly reduced FCS-induced PDGF A and B chain gene expression, completely abolished the PDGF A and B chain gene expression induced by phorbol 12-myristate 13-acetate, a specific protein kinase C activator, suggesting a site of action downstream of this enzyme in the mitogenic signal transduction pathway.
Unknown
Name Type Language
RAMIPRIL
EP   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
CARDACE
Brand Name English
Ramipril [WHO-DD]
Common Name English
RAMIPRIL [USP-RS]
Common Name English
HOPACE
Brand Name English
CYCLOPENTA(B)PYRROLE-2-CARBOXYLIC ACID, 1-((2S)-2-(((1S)-1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)AMINO)-1-OXOPROPYL)OCTAHYDRO-, (2S,3AS,6AS)-
Common Name English
RAMIPRIL [JAN]
Common Name English
DELIX
Brand Name English
ALTACE
Brand Name English
RAMIPRIL, (+)-
Common Name English
ramipril [INN]
Common Name English
C09AA05
Code English
RAMIPRIL [USP MONOGRAPH]
Common Name English
CORPRIL
Brand Name English
HOE 498
Code English
CYCLOPENTA(B)PYRROLE-2-CARBOXYLIC ACID, 1-(2-((1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)AMINO)-1-OXOPROPYL)OCTAHYDRO-, (2S-(1(R*(R*)),2.ALPHA.,3A.BETA.,6A.BETA.))-
Common Name English
TRIATEC
Common Name English
POLYCAP COMPONENT RAMIPRIL
Brand Name English
HOE-498
Code English
RAMACE
Brand Name English
RAMIPRIL [VANDF]
Common Name English
RAMIPRIL [EP MONOGRAPH]
Common Name English
RAMIPRIL [ORANGE BOOK]
Common Name English
RAMIPRES
Brand Name English
NSC-758933
Code English
RAMIPRIL [MI]
Common Name English
PRAMACE
Brand Name English
ECATOR
Brand Name English
TRITACE
Brand Name English
UNIPRIL
Brand Name English
(2S,3aS,6aS)-1-[(S)-N-[(S)-1-Carboxy-3-phenylpropyl]alanyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid, 1-ethyl ester
Common Name English
RAMIPRIL [USAN]
Common Name English
RAMIPRIL [MART.]
Common Name English
VESDIL
Brand Name English
Classification Tree Code System Code
WHO-ATC C09BB07
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
WHO-VATC QC09BB05
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
WHO-ATC C09BB05
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
WHO-VATC QC09BA05
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
WHO-VATC QC09BB07
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
WHO-ATC C10BX04
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
WHO-VATC QC09AA05
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
WHO-ATC C09BA05
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
WHO-ATC C09BX03
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
NDF-RT N0000000181
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
LIVERTOX NBK548689
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
WHO-VATC QC10BX04
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
WHO-ATC C09AA05
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
WHO-ATC C10BX06
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
NDF-RT N0000175562
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
NCI_THESAURUS C247
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL1168
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
INN
5561
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
WIKIPEDIA
RAMIPRIL
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
DRUG CENTRAL
2356
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
CHEBI
8774
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
DRUG BANK
DB00178
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
SMS_ID
100000092240
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
EVMPD
SUB10248MIG
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
CAS
87333-19-5
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
FDA UNII
L35JN3I7SJ
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
DAILYMED
L35JN3I7SJ
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
NCI_THESAURUS
C29411
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
MESH
D017257
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
RS_ITEM_NUM
1598303
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
NSC
758933
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
LACTMED
Ramipril
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
RXCUI
35296
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY RxNorm
USAN
X-65
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
IUPHAR
6339
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
EPA CompTox
DTXSID8023551
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
MERCK INDEX
m9491
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY Merck Index
PUBCHEM
5362129
Created by admin on Fri Dec 15 15:04:06 GMT 2023 , Edited by admin on Fri Dec 15 15:04:06 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of RAMIPRILAT
SUBSTANCE RECORD
Structure of RAMIPRIL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966